Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer
Barroso-Sousa R, Vaz-Luis I, Di Meglio A, Hu J, Li T, Rees R, Sinclair N, Milisits L, Leone JP, Constantine M, Faggen M, Briccetti F, Block C, Partridge A, Burstein H, Waks AG, Tayob N, Trippa L, Tolaney SM, Hassett MJ, Winer EP, Lin NU. Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. The Oncologist 2021, 26: 927-933. PMID: 34472667, PMCID: PMC8571744, DOI: 10.1002/onco.13960.Peer-Reviewed Original ResearchConceptsGrade hypersensitivity reactionsHypersensitivity reactionsPaclitaxel cyclesCycle 3Breast cancerCycle 1Grade 2 hypersensitivity reactionGrade 3 hypersensitivity reactionDose-dense doxorubicinDose-dense paclitaxelGrade 3 eventsUse of corticosteroidsEarly breast cancerSingle-arm studyAdministration of antihistaminesHistamine H2 blockersCycle 2Corticosteroid premedicationDd ACDexamethasone premedicationPaclitaxel regimenPremedication protocolDexamethasone usePaclitaxel doseProtocol therapy